Ongoing Research Projects (as of Jan 2024)

PBMA’s H.V.Desai Eye Hospital team has been involved in the following clinical research projects some of them are ongoing as of Jan, 2024.

No. Sponsor Protocol No Protocol Title Department
1 Genentech, Inc. ML43435 A Phase IIIb, Multicenter, Open-Label, Single-Arm Study To
Investigate Faricimab (Ro6867461) Treatment Response
In Treatment-Naïve, Underrepresented Asian Indian
Patients With Diabetic Macular Edema.		 Retina
2 Opthea, Australia OPT-302-1004 OPTHEA: A Phase III, Multicenter, Double-Masked, Randomised
Study To Evaluate The Efficacy And Safety Of
Intravitreal OPT-302 In Combination With Ranibizumab,
Compared With Ranibizumab Alone, In Participants With
Neovascular Age-Related Macular Degeneration.		 Retina
3 Velux Foundation - A Regenerative Bioadhesive For The Treatment Of Infected Corneal Ulcers. Cornea

Completed Research Projects

The following Research projects conducted in collaboration with other research Institutions, Universities and others partners in Medical & Pharma industry, were completed at our eye hospital.

No. Sponsor Protocol No Protocol Title Department
1 Lux Bioscience 1. LX201-01 A multi center, placebo –controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for prevention of corneal Allograft Rejection episodes and graft failure following penetrating ketatoplasty with LX 201 implantation in subjects who are at increased immunological Risk. Cornea
2 Lux Bioscience 2. LX 201-02 A multi center, placebo– controlled, randomized, Parallel-group, Dose Ranging study to access the efficacy and safety of LX201 for the prevention of corneal allograft rejection episodes Or Graft failure in subjects who experienced one or more rejection episodes following penetrating keraoplasty. Cornea
3 Sun Pharma Advance Research Company CLR_08_01 Comparison of the efficacy and safety of Latanoprost 0.005% (Xalatan ® Reference) and Latanoprost 0.005% administered once daily in open angle glaucoma and ocular hypertension. Glaucoma
4 Sun Pharma Advance Research Company, Mumbai CLR_10_31 Study to evaluate Safety of Benzalkonium Chloride Free Latanoprost Ophthalmic Solution 0.005% in Subjects with Glaucoma. Glaucoma
5 Allergan Health Care India Pvt Ltd. 192024-049 Efficacy and safety of fixed dose combination of latanoprost 0.005% and timolol 0.5% ophthalmic solution (sun pharma advanced research company Ltd.) in patients with open angle glaucoma or ocular hypertension: a randomized, evaluator masked, parallel Group, active controlled study. Glaucoma
6 Foresight Biotherapeutics, Inc. New York, USA FST100-AVC-004 A proof-of-concept, multi-center, randomized, double-masked study to evaluate the Clinical efficacy and safety of FST-100 (0.1% Dexamethasone and 0.6 % PVP-Iodine ) Ophthalmic suspension in the treatment of Acute Adenoviral conjunctivitis. Cornea
7 Intas Biopharmaceutical Ltd. Ahmedabad. IBPL_RN_01 A Prospective, Comparative, Assessor Blind, Randomized, Multicenteric Phase III study to compare the safety and efficacy of Ranibizumab of Intas Biopharmaceuticals Ltd. in comparison with Lucentis of Novartis in patients of wet AMD (Age related Macular Degeneration). Retina
8 Sun Pharma Advance Research Company, Mumbai. CLR_11_07 “Aqueous Humor Bioequivalence Study of Loteprednol 0.5 %, Sun Pharmaceutical Industries Ltd. (SPIL) and Lotemax in Patients Undergoing Cataract Surgery: A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Cross over, Active Controlled Study”. Cataract
9 Sun Pharmaceutical Ltd., Mumbai SUB/SFCB/0110 “Evaluation and efficacy and safety of two fixed dose combination of carbonic anhydrate inhibitor and beta blocker for the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma a randomized open label, comparative, multicentric study.” Glaucoma
10 Lotus Lab, Bangalore WAT/BNZL/2014 A multicentre, double blind, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint comparing Brinzolamide 1% ophthalmic suspension (manufactured by Indoco Remedies Ltd., for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% ophthalmic suspension of Alcon Laboratories Inc., in the treatment of Chronic open angle glaucoma or Ocular hypertension in both eye. Glaucoma
11 Alcon Laboratories India Pvt., Ltd. EXJ821-P001 (C-13-039) Clinical Evaluation of Systane® Balance on Corneal Staining in Indian Subjects with Dry Eye. Cornea
12 Lotus Lab, Bangalore WAT/LTPNL/2015 An Open Label, Randomized, Multicentric, Two Treatment, Single Dose, Parallel Group Two Stage Adaptive Design Bioequivalence Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5 % in Aqueous Humor of Patients Undergoing Indicated Cataract Surgery”. Cataract
13 pSivida Corp., Watertown, MA 02472 USA PSV-FAI-001 A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. Retina
14 Clearside Biomedical Inc , USA CLS1001-301 (PEACHTREE) A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema associated with Non-Infectious UvEitis0 Retina
15 Intas Pharmaceutical, Ahmedabad 045-15 A prospective, multicenter clinical study to assess safety immunogenicity and efficacy of Ranibizumab (Intas Pharmaceutical Limited) for the treatment of wet AMD (Age Related Macular Degeneration). Retina
16 Clearside Biomedical Inc , USA CLS1003-302. Topaz A randomized, masked controlled trial to study the safety and efficacy of superchoroidal CLS-TA in combination with intravitreal anti-VEGF agent in subjects with retinal vein occlusion. Retina
17 pSivida Corp, Watertown, MA 02472 USA PSV-FAI-005 A Multi-Center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis affecting the Posterior Segment of the Eye. Retina
18 Quark pharmaceutical, USA QRK207 A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI- 1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). Retina
19 IVIEW Therapeutics, Inc., USA IVIEW-1201-01-AIC A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis. Cornea
20 Pharmathen S.A., Greece 20-VIN-0084 A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint between Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (Pharmathen S.A, Greece) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. Glaucoma
21 CRO: Syneos Health, USA XBR1001 Xplore: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration Retina
22 OcuNexus Therapeutics. Inc., USA NEX-PED-005, A Phase 2, randomized, prospective, double-masked, vehicle-controlled study to assess the efficacy and safety of Nexagon® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries. Cornea
23 Sun Pharmaceutical Industries. Mumbai ICR/19/016 A randomized, multicenter, active controlled, parallel-group study to access efficacy and safety of fixed dose combination of Netarsudil and Latanoprost Ophthalmic solution (0.02% w/v) +(0.005% w/v) in comparison with Latanoprost eye drops (0.005% w/v) in patients with open angle glaucoma or ocular hypertension. Glaucoma
24 CRO: Syneos Health, USA QL1205-002 A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration. Retina
25 Santen Incorporated, USA 010906IN LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. Retina
26 Thea Laboratories, France LT4030-301 Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort ® UD in Ocular Hypertensive or Glaucomatous Patients. Glaucoma
27 Celltrion, Korea CT-P42 3.1 A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema. Retina

PBMA’s H.V.Desai Eye Hospital team has the ongoing clinical research projects as of Jan, 2024


  1. Protocol Title: Efficacy and Reactivation rates between Biosimilar and Innovator Ranibizumab in Aggressive retinopathy of prematurity—A prospective multicentre cohort study.
  2. Protocol Title: Outcome of Kahook Dual Blade goniotomy in patients with mild to moderate glaucoma undergoing phacoemulsification.
  3. Protocol Title: Relationship of vessel density by Optical Coherence Tomography Angiography in healthy, glaucoma suspects and glaucoma patients in Western Maharashtra.
  4. Protocol Title: Clinical presentation and management strategies in Juvenile open angle glaucoma (JOAG ).
  5. Protocol Title: Study of biometric parameters measured with TOPCON MYAH device compared to Zeiss IOL master 700 in myopic kids in Indian population.
  6. Protocol Title: Factors influencing visual outcome of Pediatric cataract surgery at tertiary eye care centre, western India.
  7. Protocol Title: Comparative /Prospective study to assess efficacy of dichoptic therapy in residual amblyopia, in children above 6 yrs of age.
  8. Protocol Title: Compliance to occlusion therapy after low vision aids intervention in dense stimulus deprivation amblyopia.
  9. Protocol Title: Safety of bilateral, simultaneous intravitreal Anti VEGF injection for Retinopathy of Prematurity.
  10. Protocol Title: Study the Impact and Usability of the Pristine 5.0 Camera in Primary Eye Care Settings.
  11. Protocol Title: Global Retinoblastoma Presentation (2024) and Outcome (2027) Studies.
  12. Protocol Title: Analysis of factors responsible for need for extended systemic chemotherapy in conjunction with focal treatment in patients with Retinoblastoma (RB).
  13. Protocol Title: Refractive Outcome Of Cataract Surgery With Toric IOL.

Sitemap
SingHealth

PBMA’s H V Desai Eye Hospital

S N. 93/2 Tarawade Vasti, Mohammed Wadi, Near Corianthian Club, Hadapsar, Pune, Maharashtra, INDIA 411060

Contact

For appointments call
 +91 7276185145 / 020 26974000
Call between 8:30 am to 5:00 pm

Email: desaieyehospital@hvdeh.org
Helpline Number: +91 9870487488

© 2024 HVD. All Rights Reserved.

:::| powered by dimakh consultants |:::